SEC Filing Summary: Prima BioMed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima BioMed Ltd, a foreign private issuer, on November 19, 2013. The registrant is headquartered in Sydney, Australia, and files annual reports under Form 20-F. The filing serves to report a specific corporate governance event rather than periodic financial results.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notice of a change in director's interest and does not contain financial statements or performance data.
Material Changes
The material change disclosed in this filing is the submission of an "Appendix 3Y Change of Director's Interest Notice" (Exhibit 99.1). No financial or operational changes relative to a prior comparable period are detailed in this specific report.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is strictly a regulatory disclosure regarding a director's interest.
Key Facts for Investor Verification
- Verify the specific details of the director's interest change in the attached Exhibit 99.1 (Appendix 3Y).
- Confirm the identity of the director involved in the interest change, as the summary text only lists the CEO, Matthew Lehman, as the signatory.
- Review the company's most recent Form 20-F or quarterly reports for actual financial performance data, as this filing does not include it.